Meeting
2018 Genitourinary Cancers Symposium
The importance of the need for better systemic therapy in the definitive treatment of high-risk prostate cancer regardless of whether the initial treatment modality was external beam radiation, I-125 brachytherapy, or radical prostatectomy.
Authors
Jay P. Ciezki
Cleveland Clinic, Cleveland, OH
Jay P. Ciezki , Chandana A. Reddy , Omar Y. Mian , Jorge A. Garcia , Eric A. Klein , James Ulchaker , Kenneth Angermeier , Steven C. Campbell , Andrew J. Stephenson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 65)
DOI
10.1200/JCO.2018.36.6_suppl.65
Abstract #
65
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
The effect of maximum tumor diameter on disease control in intermediate and high-risk prostate cancer patients treated with brachytherapy boost.
First Author: Matthew Parsons
Poster
2020 Genitourinary Cancers Symposium
Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.
First Author: Amar Upadhyaya Kishan
Poster
2019 Genitourinary Cancers Symposium
External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.
First Author: Vinayak Muralidhar
Poster
2018 Genitourinary Cancers Symposium
Clinical outcomes following biochemical recurrence among patients with Gleason score 9-10 prostate adenocarcinoma.
First Author: Kiri A Sandler